Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,937 matching trials from the live ClinicalTrials.gov search.
Conditions
Human Immunodeficiency Virus
Interventions
Lenacapavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
Interventions
Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy, Non-myeloablative Conditioning regimen, Allogeneic transplant, Autologous transplant, Rituximab maintenance therapy, GVHD Prophylaxis
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
30
States / cities
Duarte, California • La Jolla, California • Stanford, California + 23 more
Conditions
Drug Abuse
Interventions
Brief advice, Brief Intervention plus Booster, Brief Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Austin, Texas
Conditions
HIV/AIDS, Medication Adherence
Interventions
Proteus digital health feedback (PDHF) system
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
17 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Photoaging, Wrinkle, Skin Laxity
Interventions
Hybrid Fractional Laser, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Dallas, Texas
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Loma Linda, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Opioid Use Disorder
Interventions
Embodied conversational agent (ECA), Technical support, Additional ECA messages, Additional incentives
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Recruiting Not applicable Interventional Accepts healthy volunteers

Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes

NCT05642715
Conditions
Hiv, Tobacco Use
Interventions
EX+, Varenicline, HR, TAU
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
40 Years to 79 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Nicotine Replacement Therapy, Diet
Drug · Behavioral
Lead sponsor
Mark Vander Weg
Other
Eligibility
Not listed
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Conditions
Hair Thinning, Hair Shedding
Interventions
Scale HLV Clinical Formula Hair Vitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Scale Media Inc
Industry
Eligibility
35 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Not yet recruiting Not applicable Interventional

Trial of NASHA Dx Urethral Bulking System

NCT07850804
Conditions
Urinary Incontinence, Urinary Incontinence (UI), Urinary Incontinence , Stress, Urinary Incontinence Due to Urethral Sphincter Incompetence, Urethral Sphincter Activity, Intrinsic Sphincter Deficiency, Pelvic Floor Dysfunction
Interventions
NASHA Dx, Bulkamid
Device
Lead sponsor
Palette Life Sciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Tustin, California • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Conditions
Chronic Nonmalignant Pain, Pain, Intractable, Pain, Chronic
Interventions
Flowonix Prometra® II Programmable Infusion System, Pain Medicine
Device · Drug
Lead sponsor
Evolve Restorative Center
Other
Eligibility
22 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Rosa, California
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Conditions
Pompe Disease (Late-onset)
Interventions
No Intervention
Other
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
16 Years to 69 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Atlanta, Georgia • Kansas City, Kansas • Ann Arbor, Michigan + 7 more
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatitis C, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Pablo Sanchez
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Effect of L. Paracasei Strain Shirota on Constipation in Healthy US Adults

NCT06014008
Conditions
Constipation
Interventions
Test product consumption group
Other
Lead sponsor
Yakult U.S.A. Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
67
States / cities
Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 55 more
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
hold hypoglycemic meds
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Coronary Artery Disease, Myocardial Ischemia, Bleeding
Interventions
clopidogrel 600 mg, arterial access sheath
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CJCV2 With and Without ALFQ

NCT05500417
Conditions
Campylobacter Infection
Interventions
ALFQ, CJCV2
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery
Drug · Procedure
Lead sponsor
Robert H. Lurie Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures

NCT01048658
Conditions
Blood Loss, Anesthesia
Interventions
Sevoflurane, No Sevoflurane
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Portland, Oregon